Evaluation of new anti-infective drugs for the treatment of acute hematogenous osteomyelitis in children

J. D. Nelson, C. Norden, J. T. Mader, G. B. Calandra

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Most children with acute hematogenous osteomyelitis have no preceding illness. Their early symptoms are pain and fever. A bacterial etiology is established in ~75% of cases by needle aspiration of the affected site or blood culture. Clinical trials should be limited to cases of bacterial origin. The antimicrobial agents studied should be active against Staphylococcus aureus and streptococci. If children <5 years of age are included, the drug should also be active against β-lactamase-negative and - positive strains of Haemophilus influenzae. Randomized, prospective, double- blind comparative studies are preferable to open, evaluator-blinded trials. Clinical outcome is appraised by physical signs and symptoms. A successful microbiological outcome consists of presumptive eradication. The final assessment should be made 1 year after completion of therapy.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume15
Issue numberSUPPL. 1
StatePublished - 1992

Fingerprint

Osteomyelitis
Haemophilus influenzae
Anti-Infective Agents
Streptococcus
Double-Blind Method
Pharmaceutical Preparations
Signs and Symptoms
Needles
Staphylococcus aureus
Fever
Clinical Trials
Pain
Therapeutics
Aspirations (Psychology)
Blood Culture

ASJC Scopus subject areas

  • Immunology

Cite this

Evaluation of new anti-infective drugs for the treatment of acute hematogenous osteomyelitis in children. / Nelson, J. D.; Norden, C.; Mader, J. T.; Calandra, G. B.

In: Clinical Infectious Diseases, Vol. 15, No. SUPPL. 1, 1992.

Research output: Contribution to journalArticle

@article{2c1a9f4f205f44ae92e29a12ba1ce288,
title = "Evaluation of new anti-infective drugs for the treatment of acute hematogenous osteomyelitis in children",
abstract = "Most children with acute hematogenous osteomyelitis have no preceding illness. Their early symptoms are pain and fever. A bacterial etiology is established in ~75{\%} of cases by needle aspiration of the affected site or blood culture. Clinical trials should be limited to cases of bacterial origin. The antimicrobial agents studied should be active against Staphylococcus aureus and streptococci. If children <5 years of age are included, the drug should also be active against β-lactamase-negative and - positive strains of Haemophilus influenzae. Randomized, prospective, double- blind comparative studies are preferable to open, evaluator-blinded trials. Clinical outcome is appraised by physical signs and symptoms. A successful microbiological outcome consists of presumptive eradication. The final assessment should be made 1 year after completion of therapy.",
author = "Nelson, {J. D.} and C. Norden and Mader, {J. T.} and Calandra, {G. B.}",
year = "1992",
language = "English (US)",
volume = "15",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Evaluation of new anti-infective drugs for the treatment of acute hematogenous osteomyelitis in children

AU - Nelson, J. D.

AU - Norden, C.

AU - Mader, J. T.

AU - Calandra, G. B.

PY - 1992

Y1 - 1992

N2 - Most children with acute hematogenous osteomyelitis have no preceding illness. Their early symptoms are pain and fever. A bacterial etiology is established in ~75% of cases by needle aspiration of the affected site or blood culture. Clinical trials should be limited to cases of bacterial origin. The antimicrobial agents studied should be active against Staphylococcus aureus and streptococci. If children <5 years of age are included, the drug should also be active against β-lactamase-negative and - positive strains of Haemophilus influenzae. Randomized, prospective, double- blind comparative studies are preferable to open, evaluator-blinded trials. Clinical outcome is appraised by physical signs and symptoms. A successful microbiological outcome consists of presumptive eradication. The final assessment should be made 1 year after completion of therapy.

AB - Most children with acute hematogenous osteomyelitis have no preceding illness. Their early symptoms are pain and fever. A bacterial etiology is established in ~75% of cases by needle aspiration of the affected site or blood culture. Clinical trials should be limited to cases of bacterial origin. The antimicrobial agents studied should be active against Staphylococcus aureus and streptococci. If children <5 years of age are included, the drug should also be active against β-lactamase-negative and - positive strains of Haemophilus influenzae. Randomized, prospective, double- blind comparative studies are preferable to open, evaluator-blinded trials. Clinical outcome is appraised by physical signs and symptoms. A successful microbiological outcome consists of presumptive eradication. The final assessment should be made 1 year after completion of therapy.

UR - http://www.scopus.com/inward/record.url?scp=0026452519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026452519&partnerID=8YFLogxK

M3 - Article

C2 - 1477224

AN - SCOPUS:0026452519

VL - 15

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 1

ER -